Jianhui Ma

8PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersMolecular targetsElectrochemical energy storage and conversionGlycoconjugatesCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 26, 2026
Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

|Dec 12, 2025
The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

Jianhui Ma, Sayee Hegde, Masha Sergeeva

|Jul 14, 2025
Discovery of ZN-c5, an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) with Improved Pharmacokinetics.

Sayee G Hegde, Peter Q Huang, Kevin D Bunker

|May 20, 2025
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor Degrader.

Guobao Zhang, Peter Q Huang, Kevin D Bunker

|Apr 15, 2025
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.

Jianhui Ma, Wen Liu, Jiali Li

|Jan 14, 2025
The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.

Nathan M Jameson, Daehwan Kim, Catherine Lee

Pageof 2

Frequent Collaborators

4 joint publications

Kevin D Bunker

3 joint publications

Mark R Lackner

3 joint publications

Olivier Harismendy

2 joint publications

Nathan M Jameson